Type 2 DM is one of the major risk factors for development of non-alcoholic fatty liver
disease. The pooled prevalence of fatty liver among diabetics is 54% (95% CI 45%-64%). Until
now there is no well-established treatment for fatty liver disease.
Study setting: Randomized controlled trial
Study population:
Patients with type 2 DM plus Fatty Liver.
Arms and Interventions
1. Experimental arms: Group 1: metformin +/- insulin +/- sulfonylurea Group 2: Metformin plus
vildagliptin+/- insulin +/- sulfonylurea Group 3: Metformin plus liraglutide+/- insulin+/-
sulfonylurea Group 4: Metformin plus empagliflozin +/- insulin +/- sulfonylurea